Quantcast

Latest BioSpecifics Technologies Corp. Stories

2011-03-10 15:15:00

LYNBROOK, N.Y., March 10, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011, at 11:30 a.m. Pacific Time at the Ritz Carlton in Laguna Niguel, California. A live webcast of the presentation can be accessed under "Calendar of...

2011-03-08 15:30:00

LYNBROOK, N.Y., March 8, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30 am ET on March 11, 2011 to report its fourth quarter and full year 2010 financial results and corporate highlights. To participate in the conference call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The...

2011-03-03 15:54:00

LYNBROOK, N.Y., March 3, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011, at 1:45pm ET at the Boston Marriott Copley Place in Boston, Massachusetts. A live webcast of the presentation can be accessed under "Calendar of...

2011-03-01 07:00:00

LYNBROOK, N.Y., March 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced that Pfizer Inc. ("Pfizer") received approval from the European Medicines Agency ("EMA") to market XIAPEX (collagenase clostridium histolyticum) in Europe for the treatment of Dupuytren's contracture, a debilitating disorder resulting from excessive collagen deposition that causes...

2011-02-07 08:35:00

LYNBROOK, N.Y. Feb. 7, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company" or "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced that its Board of Directors has amended its Rights Agreement (the "Rights Agreement"), adopted May 14, 2002 and previously amended June 19, 2003 (the "Amendment"). The Amendment increases the ownership threshold for determining "Acquiring Person" status under the Rights...

2011-01-06 16:39:00

LYNBROOK, N.Y., Jan. 6, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company" or "BioSpecifics"), a biopharmaceutical company developing first in class collagenase-based products, today announced promising results from its study Chien-802 showing dramatic reductions in canine lipoma following injections with purified injectable collagenase. These results build upon an earlier dose escalation study from which the Company selected the dose for Chien-802. The...

2010-12-07 15:35:00

LYNBROOK, N.Y., Dec. 7, 2010 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium...

2010-11-10 07:30:00

LYNBROOK, N.Y., Nov. 10, 2010 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010, at 2:45 pm ET at The St. Regis in New York, New York. A live webcast of the presentation can be accessed under "Calendar of...

2010-11-08 05:30:00

LYNBROOK, N.Y., Nov. 8, 2010 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC) (the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2010. "We are thrilled that our continued efforts to develop collagenase have been recognized by the grants awarded to us by the government under the Qualifying Therapeutic Discovery Project Program, which...

2010-11-03 15:05:00

LYNBROOK, N.Y., Nov. 3, 2010 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC) (the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced that it has received $426,000 in grant funding under the Qualifying Therapeutic Discovery Project (QTDP) Program. The program, funded through the US Patient Protection and Affordable Care Act of 2010, supports therapeutic discovery programs. "We are very excited that the government has...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related